rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy
Clicks: 158
ID: 186109
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
158 views
28 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #113 of 250 articles by views in indian journal of pharmacology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 250 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Although most patients with autoimmune hepatitis (AIH) respond to treatment with prednisone and/or azathioprine, some patients are intolerant or refractory to standard therapy. Rituximab is an anti-CD20 monoclonal antibody that depletes B cells and has demonstrated efficacy in other autoimmune conditions.
| Reference Key |
burak2013canadianrituximab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Kelly W Burak;Mark G Swain;Tania Santodomino-Garzon;Samuel S Lee;Stefan J Urbanski;Alexander I Aspinall;Carla S Coffin;Robert P Myers |
| Journal | indian journal of pharmacology |
| Year | 2013 |
| DOI |
10.1155/2013/512624
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.